Variable | PSP cases (N = 1042) | CBD cases (N = 171) | Controls (N = 910) |
---|---|---|---|
Age (years) | 75 (45, 98) | 70 (46, 96) | 79 (41, 102) |
Sex | Â | Â | Â |
 Male | 564 (54.1%) | 89 (52.0%) | 388 (42.6%) |
 Female | 478 (45.9%) | 82 (48.0%) | 522 (57.4%) |
Age of onset (years) | 68 (41, 90) | – | – |
Disease duration (years) | 7 (1, 32) | – | – |
PSP clinical subtype | Â | Â | Â |
 Richardson | 568 (74.4%) | – | – |
 Non-Richardson | 195 (25.6%) | – | – |
Braak stage | Â | Â | Â |
 0 | 113 (14.8%) | 20 (13.3%) | – |
 I | 127 (16.6%) | 32 (21.3%) | – |
 II | 223 (29.2%) | 50 (33.3%) | – |
 III | 234 (30.6%) | 39 (26.0%) | – |
 IV | 50 (6.5%) | 7 (4.7%) | – |
 V | 11 (1.4%) | 1 (0.7%) | – |
 VI | 6 (0.8%) | 1 (0.7%) | – |
Thal phase | Â | Â | Â |
 0 | 336 (44.0%) | 82 (54.7%) | – |
 1 | 125 (16.4%) | 30 (20.0%) | – |
 2 | 52 (6.8%) | 14 (9.3%) | – |
 3 | 188 (24.6%) | 19 (12.7%) | – |
 4 | 43 (5.6%) | 3 (2.0%) | – |
 5 | 20 (2.6%) | 2 (1.3%) | – |
CB tau pathology score | 1.50 (0.25, 2.36) | 0.76 (0.23, 1.75) | – |
NFT tau pathology score | 2.23 (0.83, 2.89) | 2.19 (0.99, 2.67) | – |
TA/AP tau pathology score | 1.00 (0.06, 2.00) | 0.52 (0.24, 1.04) | – |
NT tau pathology score | 2.15 (0.35, 2.90) | 2.52 (1.23, 2.95) | – |